These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36356462)

  • 21. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study of predictors of bone metastasis in prostate cancer cases.
    Ho CC; Seong PK; Zainuddin ZM; Abdul Manaf MR; Parameswaran M; Razack AH
    Asian Pac J Cancer Prev; 2013; 14(5):3289-92. PubMed ID: 23803117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical parameters and nomograms for predicting lymph node metastasis detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
    Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients.
    Peng C; Juan C; Mao W; Jinghe Y; Renli T
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3832-3839. PubMed ID: 35731052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
    Larson SR; Zhang X; Dumpit R; Coleman I; Lakely B; Roudier M; Higano CS; True LD; Lange PH; Montgomery B; Corey E; Nelson PS; Vessella RL; Morrissey C
    Prostate; 2013 Jun; 73(9):932-40. PubMed ID: 23334979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
    Lin Y; Mao Q; Chen B; Wang L; Liu B; Zheng X; Xie L
    BMC Urol; 2017 Jun; 17(1):41. PubMed ID: 28606069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool.
    De Nunzio C; Leonardo C; Franco G; Esperto F; Brassetti A; Simonelli G; Dente D; De Dominicis C; Tubaro A
    World J Urol; 2013 Apr; 31(2):365-9. PubMed ID: 22576696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
    Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
    Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.
    Szot W; Kostkiewicz M; Zając J; Owoc A; Bojar I
    Ann Agric Environ Med; 2014; 21(4):888-92. PubMed ID: 25528940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
    Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
    Cheng Y; Luo LP; Hu S; Li LN; Wu C; Wu B; Wang DW
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):876-881. PubMed ID: 33113631
    [No Abstract]   [Full Text] [Related]  

  • 36. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study.
    Thomsen FB; Westerberg M; Garmo H; Robinson D; Holmberg L; Ulmert HD; Stattin P
    PLoS One; 2020; 15(1):e0228447. PubMed ID: 31995611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups].
    Rusu D; Rusu V; Stefănescu C; Rusu M; Răileanu I; Stătescu AM
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):476-83. PubMed ID: 20700990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.